Hims & Hers ($HIMS) Positions for $2.2B Market as Proposed Peptide Compounding Policy Advances

Hims & Hers Health ($HIMS) continues to build out infrastructure targeting the broader therapeutic peptide space as regulatory momentum accelerates in Washington. Investor attention has centered on a proposed Department of Health and Human Services (HHS) and FDA interim access policy regarding compounded peptides—including compounds such as BPC-157—which recently advanced to White House review following earlier advisory committee endorsements.
Leerink estimates the addressable U.S. telehealth peptide segment could reach $2.2 billion, projecting Hims could capture roughly 20% market share as it leverages the California peptide production facility acquired in early 2025. The expansion serves as a secondary growth driver alongside its core commercial GLP-1 partnerships and European rollout, though management maintains that commercial distribution remains contingent on final FDA rulemaking.